{'fraction_non_alphanumeric': 0.058629232039636665, 'fraction_numerical': 0.03303055326176713, 'mean_word_length': 4.637209302325582, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Study of gene polymorphism responsible for metabolism of proton pump inhibitors in children with H. pylori infection: is there a correlation with efficacy of eradication treatment?].

UNLABELLED
THE AIM of this study was to determine the effects of CYP2C19 polymorphism on H. pylori eradication in pediatric population in the Republic of Bashkortostan.


METHODS
Fifty-nine children were entered into the study (age range: 12 to 17; 22 female). All the patients were infected with H. pylori and received the combination of omeprazole (1 mg/kg/day), furazolidone (10 mg/kg/day) and amoxicilline (25 mg/kg/day) or clarithromycin (7.5 mg/kg/day) for 10 days. The participants were classified into 3 groups according to CYP2C19 genotype; rapid metabolizers (RM) (54.2%), intermediate metabolizers (IM) (35.6%) and poor metabolizers (PM) (10.2%). H. pylori infection status was assessed before and after the treatment.


RESULTS
The eradication rate was 65.6% for RM, 71.4% for IM, and 83.3% for PM.


CONCLUSION
The present study confirmed the low eradication rate for RM and for the IM groups. Alternative regimens expected to be with a higher eradication rate should be recommended (rabeprazole-based treatment).